Cytovia Therapeutics has entered into a licensing agreement with the National Cancer Institute (NCI) to develop a new “off-the-shelf” immunotherapy for solid tumors. The immunotherapy is based on “natural killer” or NK immune cells, which have been genetically modified to produce a chimeric antigen receptor, or CAR, that targets a specific cancer protein, Cytovia said in a press release detailing the new collaboration. The agreement licenses to NCI the use of NK cells modified to…
You must be logged in to read/download the full post.
The post Cytovia, NCI Team Up to Develop CAR NK-cell Therapy for Solid Tumors appeared first on BioNewsFeeds.